Rabbit Anti-Human HYOU1 Polyclonal Antibody

Background: Breast cancer (BC) is a heterogeneous disease for which the commonly used chemotherapeutic agents primarily include the anthracyclines (doxorubicin, epirubicin), microtubule inhibitors (paclitaxel, docetaxel, eribulin), and alkylating agents (cyclophosphamide). While these drugs can be highly effective, metastatic tumours are frequently refractory to treatment or become resistant upon tumour relapse. Methods: We undertook a cell polarity/epithelial mesenchymal plasticity (EMP)-enriched short hairpin RNA (shRNA) screen in MDA-MB-468 breast cancer cells to identify factors underpinning heterogeneous responses to three chemotherapeutic agents used clinically in breast cancer: Doxorubicin, docetaxel, and eribulin. shRNA-transduced cells were treated for 6 weeks with the EC10 of each drug, and shRNA representation assessed by deep sequencing. We first identified candidate genes with depleted shRNA, implying that their silencing could promote a response. Using the Broad Institute's Connectivity Map (CMap), we identified partner inhibitors targeting the identified gene families that may induce cell death in combination with doxorubicin, and tested them with all three drug treatments. Results: In total, 259 shRNAs were depleted with doxorubicin treatment (at p < 0.01), 66 with docetaxel, and 25 with eribulin. Twenty-four depleted hairpins overlapped between doxorubicin and docetaxel, and shRNAs for TGFB2, RUNX1, CCDC80, and HYOU1 were depleted across all the three drug treatments. Inhibitors of MDM/TP53, TGFBR, and FGFR were identified by CMap as the top pharmaceutical perturbagens and we validated the combinatorial benefits of the TGFBR inhibitor (SB525334) and MDM inhibitor (RITA) with doxorubicin treatment, and also observed synergy between the inhibitor SB525334 and eribulin in MDA-MB-468 cells. Conclusions: Taken together, a cell polarity/EMP-enriched shRNA library screen identified relevant gene products that could be targeted alongside current chemotherapeutic agents for the treatment of invasive BC.

To clarify whether sexual arousal could be enhanced by hypoxia, and to explain the pathogenesis of autoerotic death (AED)/autoerotic asphyxiation (AEA), we investigated the molecular-biological and hormonal interactions in male rats between hypoxia (10% O-2) and sexual stimulation (placing male rats with oestrous female rats) using hypothalamus tissue and serum. Serum oxytocin concentration was significantly increased by either hypoxia or sexual stimulation without significant change of Oxt mRNA expression. Serum concentration of adrenocorticotropic hormone was significantly elevated by sexual stimulation, although serum concentration of copeptin was significantly suppressed by hypoxia. Moreover, serum concentration of luteinising hormone was increased by hypoxia. These results suggested that hypoxia would complicatethe response to sexual stimulation, and effect a change in sexual arousal. Moreover, sexual stimulation significantly suppressed mRNA expressions of Hspa4 and Hyou1, which might indicate that sexual stimulation reducestolerance to hypoxia/ischaemia. Accordingly, it is possible that AED/AEA would be attributed to a reduced tolerance to hypoxia/ischaemia induced byattempts to obtain sexual arousal under a hypoxic condition and would not be a simple accident.